Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2014-208203 http://scihub22266oqcxt.onion/10.1136/bcr-2014-208203 C4369036!4369036!25733089     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Case+Rep 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=25733089|t=2015. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?|pdf=|usr=}}{{25733089}} gab.com Text Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=25733089 #FOAvip Rituximab is used for treatment of multiple haematological cancers. Caution for use is advised in patients with significant cardiorespiratory disease due to known cases of exacerbations of angina and arrhythmias. However, its cardiotoxicity profile is not as well recognised as other monoclonal antibodies such as transtuzumab. We report a case of a 66-year-old man who developed Takotsubo's cardiomyopathy (TC) after an elective infusion of rituximab. This case is exceptional in that rituximab has not been linked to TC, and the vast majority of chemotherapy-linked and immunotherapy-linked TC reactions have occurred during initial infusions. We also discuss the different mechanisms which link TC to immunotherapy and chemotherapy, and propose that there may be a potential for risk-stratifying recipients of this frequently used immunotherapy prior to administering treatment. Twit Text FOAVip Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=25733089 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25733089 #FOAvip English Wikipedia <ref>{{Cite pmid|25733089}}</ref> Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? #MMPMID25733089 Ng KH; Dearden C; Gruber P BMJ Case Rep 2015[]; 2015 (ä): ä PMID25733089show ga Rituximab is used for treatment of multiple haematological cancers. Caution for use is advised in patients with significant cardiorespiratory disease due to known cases of exacerbations of angina and arrhythmias. However, its cardiotoxicity profile is not as well recognised as other monoclonal antibodies such as transtuzumab. We report a case of a 66-year-old man who developed Takotsubo's cardiomyopathy (TC) after an elective infusion of rituximab. This case is exceptional in that rituximab has not been linked to TC, and the vast majority of chemotherapy-linked and immunotherapy-linked TC reactions have occurred during initial infusions. We also discuss the different mechanisms which link TC to immunotherapy and chemotherapy, and propose that there may be a potential for risk-stratifying recipients of this frequently used immunotherapy prior to administering treatment. äRituximab-induced Takotsubo syndrome: more cardiotoxic than it appears(epmc).pdf DeepDyve Pubget Overpricing